Q-omics provides the consensus-scored NUP210P3 profile across patient tissues and cancer cell-line models. NUP210P3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NUP210P3 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, NUP210P3 RNA expression shows 13,979 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, THCA, and TGCT as cancer lineages where NUP210P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP210P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP210P3 survival associations across molecular data types. NUP210P3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP210P3 RNA expression–survival associations across cancer types. High NUP210P3 expression shows unfavorable associations in COAD, STAD, MESO and THCA, but favorable associations in BRCA and LUAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for NUP210P3 RNA expression.
This table summarizes NUP210P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NUP210P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP210P3 shows lower tumor expression in KICH and BRCA and higher tumor expression in THCA, LIHC, CHOL and PRAD. The THCA box plot shows higher NUP210P3 RNA expression in tumor versus normal tissue (log2 FC = +0.283, t-test p = .002).
This table shows molecular features associated with NUP210P3 in patient tissues and cancer cell lines. In patient samples, NUP210P3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
